Story perspectives

UCLA Trial Finds Enol-Oxaloacetate Boosts Cognitive Performance, Fatigue

By Drooid · Oct 26, 2026, 11:38 PM UTC · How we work

Summary

UCLA Researchers Improve Cognition

UCLA researchers gave oxaloacetate supplements to breast cancer survivors, reporting cognitive improvement.
Participants took 500 mg anhydrous enol-oxaloacetate capsules twice daily for eight weeks.
Mean FACT-Cog PCI score rose from 29 to 55.5, exceeding the 54 impairment threshold.
All 16 women who completed the trial reported reduced fatigue and marked physical-function gains.
Researchers noted two early dropouts from severe diarrhea and gastrointestinal issues and plan a larger phase-two placebo-controlled trial.

Summary

Faroese Survivors Report Challenges

A qualitative study of seven Faroese breast cancer survivors was published in Frontiers in Oncology.
The participants, aged 49-68, completed treatment between 2011 and 2024 and were recruited via the Faroese Cancer Society.
Survivors described an emotional rupture at discharge, feeling abandoned, shocked, and lonelier than during diagnosis.
Late effects reported include sensory disturbances, cognitive lapses, balance problems, reduced work hours, and hobby limitations.

Summary

Women Endure Relentless Fatigue

Survivors said treatment-related fatigue feels relentless and more draining than ordinary tiredness.
She likened house cleaning to a marathon that left her exhausted for a month.
Women said they could stay active two days before crashing completely on the third.
Fatigue made several women quit jobs or retire early, leaving others returning home depleted.

1 of 3

UCLA Researchers Improve Cognition

UCLA researchers gave oxaloacetate supplements to breast cancer survivors, reporting cognitive improvement.
Participants took 500 mg anhydrous enol-oxaloacetate capsules twice daily for eight weeks.
Mean FACT-Cog PCI score rose from 29 to 55.5, exceeding the 54 impairment threshold.
All 16 women who completed the trial reported reduced fatigue and marked physical-function gains.
Researchers noted two early dropouts from severe diarrhea and gastrointestinal issues and plan a larger phase-two placebo-controlled trial.

1 / 3